Cost-Effectiveness Analysis of the Addition of Rituximab to CHOP in Young Patients with Good-Prognosis Diffuse Large-B-Cell Lymphoma

Author： Ferrara Felicetto  

Publisher： Adis International

ISSN： 1173-2563

Source： Clinical Drug Investigation, Vol.28, Iss.1, 2008-01, pp. : 55-65

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cost-Effectiveness of the Addition of Rituximab to CHOP Chemotherapy in First-Line Treatment for Diffuse Large B-Cell Lymphoma in a Population-Based Observational Cohort in British Columbia, Canada

By Johnston Karissa M.   Marra Carlo A.   Connors Joseph M.   Najafzadeh Mehdi   Sehn Laurie   Peacock Stuart J.  

Value in Health, Vol. 13, Iss. 6, 2010-09 ,pp. : 703-711

Blackwell Publishing

Access to resources Recommend Favorite

Mean platelet volume predicts prognosis in patients with diffuse large B‐cell lymphoma

By  

Hematological Oncology (Electronic), Vol. 36, Iss. 1, 2018-02 ,pp. : 104-109

John Wiley & Sons Inc

Access to resources Recommend Favorite

Rituximab: A Review of its Use in Chronic Lymphocytic Leukaemia, Low-Grade or Follicular Lymphoma and Diffuse Large B-Cell Lymphoma

By Keating Gillian M.  

Drugs, Vol. 70, Iss. 11, 2010-07 ,pp. : 1445-1476

Adis International

Access to resources Recommend Favorite

Rituximab + CHOP: first-line therapy in B-cell lymphoma

By  

Inpharma, Vol. 1, Iss. 1323, 2002-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

Deregulated Expression of miR-224 and its Target Gene: CD59 Predicts Outcome of Diffuse Large B-cell Lymphoma Patients Treated with R-CHOP

By  

Current Cancer Drug Targets, Vol. 14, Iss. 7, 2014-09 ,pp. : 659-670

Bentham Science Publishers

Access to resources Recommend Favorite